• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·POKO.CN
Share

Poko Innovations Inc. Stocks

CA$ 0Last Updated 23.03.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

CA$ 1.46M

CA$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Poko Innovations Inc. operates as a CBD and fintech company. The company offers provides skin care products for various skin types, including blemish prone, ageing, and dry skin under Poko brand; and operates Lumipay, a payment gateway service focusing on the CBD industry. It also operates Candid Magazine, a B2C lifestyle and culture magazine that covers lifestyle focused products, CBD celebrity news, and cultural events; CBD Village, an e-commerce and review site that offers a wide variety of CBD brands and products; The Extract, a B2B focused online news and media space; Canndid CBD products; Cannmed products, a wholesale premium white labelling and raw materials marketplace; and Cannmed Marketplace. Poko Innovations Inc. is based in London, United Kingdom.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.08.2026 10:22

Top Stories This Morning: Palantir Sets Records, Snap Reports Strong Results, and a Lawsuit Against Revolut's Founder

04.08.2026 09:00

Trump criticized ExxonMobil and Chevron over their record profits and gas prices

04.08.2026 08:00

The last "bear" rejected the advice to sell Boeing stock. What changed his mind?

04.08.2026 03:41

Palantir reported "superb" results and raised its forecasts

04.08.2026 02:10

U.S. stocks had their best start to the month in four years. The Dow hit a new record high.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026